134 related articles for article (PubMed ID: 29076004)
1. High mTOR expression independently prognosticates poor clinical outcome to induction chemotherapy in acute lymphoblastic leukemia.
Khanna A; Bhushan B; Chauhan PS; Saxena S; Gupta DK; Siraj F
Clin Exp Med; 2018 May; 18(2):221-227. PubMed ID: 29076004
[TBL] [Abstract][Full Text] [Related]
2. High expression of ID family and IGJ genes signature as predictor of low induction treatment response and worst survival in adult Hispanic patients with B-acute lymphoblastic leukemia.
Cruz-Rodriguez N; Combita AL; Enciso LJ; Quijano SM; Pinzon PL; Lozano OC; Castillo JS; Li L; Bareño J; Cardozo C; Solano J; Herrera MV; Cudris J; Zabaleta J
J Exp Clin Cancer Res; 2016 Apr; 35():64. PubMed ID: 27044543
[TBL] [Abstract][Full Text] [Related]
3. Dual targeting of MTOR as a novel therapeutic approach for high-risk B-cell acute lymphoblastic leukemia.
Ge Z; Song C; Ding Y; Tan BH; Desai D; Sharma A; Gowda R; Yue F; Huang S; Spiegelman V; Payne JL; Reeves ME; Iyer S; Dhanyamraju PK; Imamura Y; Bogush D; Bamme Y; Yang Y; Soliman M; Kane S; Dovat E; Schramm J; Hu T; McGrath M; Chroneos ZC; Payne KJ; Gowda C; Dovat S
Leukemia; 2021 May; 35(5):1267-1278. PubMed ID: 33531656
[TBL] [Abstract][Full Text] [Related]
4. Targeting mTOR in Acute Lymphoblastic Leukemia.
Simioni C; Martelli AM; Zauli G; Melloni E; Neri LM
Cells; 2019 Feb; 8(2):. PubMed ID: 30795552
[TBL] [Abstract][Full Text] [Related]
5. Targeting of hyperactivated mTOR signaling in high-risk acute lymphoblastic leukemia in a pre-clinical model.
Hasan MN; Queudeville M; Trentin L; Eckhoff SM; Bronzini I; Palmi C; Barth T; Cazzaniga G; te Kronnie G; Debatin KM; Meyer LH
Oncotarget; 2015 Jan; 6(3):1382-95. PubMed ID: 25682198
[TBL] [Abstract][Full Text] [Related]
6. Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3/HOX11L2 gene expression on outcome.
Ballerini P; Landman-Parker J; Cayuela JM; Asnafi V; Labopin M; Gandemer V; Perel Y; Michel G; Leblanc T; Schmitt C; Fasola S; Hagemejier A; Sigaux F; Auclerc MF; Douay L; Leverger G; Baruchel A
Haematologica; 2008 Nov; 93(11):1658-65. PubMed ID: 18835836
[TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96.
Eckert C; von Stackelberg A; Seeger K; Groeneveld TW; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Escherich G; Henze G
Eur J Cancer; 2013 Apr; 49(6):1346-55. PubMed ID: 23265714
[TBL] [Abstract][Full Text] [Related]
8. Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia.
Shi PJ; Xu LH; Lin KY; Weng WJ; Fang JP
J Hematol Oncol; 2016 Feb; 9():12. PubMed ID: 26892465
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.
Ribera JM; Ortega JJ; Oriol A; Granada I; Hernández-Rivas JM; Parody R; Bethencourt C; Rivas C; Bastida P; del Potro E; González-Valentín ME; Moreno MJ; Besalduch J; Fernández-Calvo J; Tormo M; Arias J; Molinés A; Sanz MA; Maldonado J; Millá F; Feliu E; San Miguel JF;
Haematologica; 2002 Feb; 87(2):154-66. PubMed ID: 11836166
[TBL] [Abstract][Full Text] [Related]
10. [Therapeutic strategies for childhood high-risk acute lymphoblastic leukemia].
Lu XT
Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 45(2):327-32. PubMed ID: 23591360
[TBL] [Abstract][Full Text] [Related]
11. Targeting the mTOR Pathway in Leukemia.
Dinner S; Platanias LC
J Cell Biochem; 2016 Aug; 117(8):1745-52. PubMed ID: 27018341
[TBL] [Abstract][Full Text] [Related]
12. Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study.
Lepretre S; Touzart A; Vermeulin T; Picquenot JM; Tanguy-Schmidt A; Salles G; Lamy T; Béné MC; Raffoux E; Huguet F; Chevallier P; Bologna S; Bouabdallah R; Benichou J; Brière J; Moreau A; Tallon-Simon V; Seris S; Graux C; Asnafi V; Ifrah N; Macintyre E; Dombret H
J Clin Oncol; 2016 Feb; 34(6):572-80. PubMed ID: 26644537
[TBL] [Abstract][Full Text] [Related]
13. XIAP expression is post-transcriptionally upregulated in childhood ALL and is associated with glucocorticoid response in T-cell ALL.
Hundsdoerfer P; Dietrich I; Schmelz K; Eckert C; Henze G
Pediatr Blood Cancer; 2010 Aug; 55(2):260-6. PubMed ID: 20582956
[TBL] [Abstract][Full Text] [Related]
14. Expression of genes related to multiple drug resistance and apoptosis in acute leukemia: response to induction chemotherapy.
Chauhan PS; Bhushan B; Singh LC; Mishra AK; Saluja S; Mittal V; Gupta DK; Kapur S
Exp Mol Pathol; 2012 Feb; 92(1):44-9. PubMed ID: 22037714
[TBL] [Abstract][Full Text] [Related]
15. IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study.
Li Y; Buijs-Gladdines JG; Canté-Barrett K; Stubbs AP; Vroegindeweij EM; Smits WK; van Marion R; Dinjens WN; Horstmann M; Kuiper RP; Buijsman RC; Zaman GJ; van der Spek PJ; Pieters R; Meijerink JP
PLoS Med; 2016 Dec; 13(12):e1002200. PubMed ID: 27997540
[TBL] [Abstract][Full Text] [Related]
16. Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia.
Forero-Castro M; Robledo C; Benito R; Bodega-Mayor I; Rapado I; Hernández-Sánchez M; Abáigar M; Maria Hernández-Sánchez J; Quijada-Álamo M; María Sánchez-Pina J; Sala-Valdés M; Araujo-Silva F; Kohlmann A; Luis Fuster J; Arefi M; de Las Heras N; Riesco S; Rodríguez JN; Hermosín L; Ribera J; Camos Guijosa M; Ramírez M; de Heredia Rubio CD; Barragán E; Martínez J; Ribera JM; Fernández-Ruiz E; Hernández-Rivas JM
Br J Cancer; 2017 Jul; 117(2):256-265. PubMed ID: 28557976
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of BCL2 and BAX following BFM induction therapy predicts ch-ALL patients' poor response to treatment and short-term relapse.
Stamati L; Avgeris M; Kosmidis H; Baka M; Anastasiou T; Piatopoulou D; Scorilas A; Gourgiotis D
J Cancer Res Clin Oncol; 2015 Nov; 141(11):2023-36. PubMed ID: 25982455
[TBL] [Abstract][Full Text] [Related]
18. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
19. A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.
Daver N; Boumber Y; Kantarjian H; Ravandi F; Cortes J; Rytting ME; Kawedia JD; Basnett J; Culotta KS; Zeng Z; Lu H; Richie MA; Garris R; Xiao L; Liu W; Baggerly KA; Jabbour E; O'Brien S; Burger J; Bendall LJ; Thomas D; Konopleva M
Clin Cancer Res; 2015 Jun; 21(12):2704-14. PubMed ID: 25724525
[TBL] [Abstract][Full Text] [Related]
20. [Effect of Huangqi injection on short-term prognosis in children with acute lymphoblastic leukemia].
Yan PH; Yan M; Wang XM; Wang SH
Zhongguo Dang Dai Er Ke Za Zhi; 2014 Feb; 16(2):141-6. PubMed ID: 24568906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
